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Objective Oncology patients are increasingly encouraged to play an active role in treatment
decision making. While previous studies have evaluated relationships between demographic
characteristics and decision‐making roles, less is known about the association of symptoms and
psychological adjustment characteristics (eg, coping styles and personality traits) and decision‐
making roles.
Methods As part of a larger study of symptom clusters, patients (n = 765) receiving chemo-
therapy for breast, gastrointestinal, gynecological, or lung cancer provided information on demo-
graphic, clinical, symptom, and psychological adjustment characteristics. Patient‐reported
treatment decision‐making roles (ie, preferred role and role actually played) were assessed using
the Control Preferences Scale. Differences among patients, who were classified as passive,
collaborative, or active, were evaluated using χ2 analyses and analyses of variance.
Results Over half (56.3%) of the patients reported that they both preferred and actually
played a collaborative role. Among those patients with concordant roles, those who were older,
those with less education and lower income, and those who were less resilient were more likely
to prefer a passive role. Several psychological adjustment characteristics were associated with
decision‐making role, including coping style, personality, and fatalism.
Conclusions Oncology patients' preferences for involvement in treatment decision making
are associated with demographic characteristics as well as with symptoms and psychological
adjustment characteristics, such as coping style and personality. These results reaffirm the com-
plexities of predicting patients' preferences for involvement in decision making. Further study is
needed to determine if role or coping style may be influenced by interventions designed to teach
adaptive coping skills.
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Shared decision making (SDM) is an important aspect of the patient‐
clinician relationship and communication processes.1 In 2001, the
Institute of Medicine encouraged overhauling the organization and
delivery of health care and highlighted SDM as a key mechanism of
patient‐centered care.2 More recently, with the passage of the
Affordable Care Act (specifically, section 3506), SDM gained even
greater prominence.3td. wileyonlinelibCancer treatment decisions are numerous, can be stressful, often
unfold over years, and have important consequences for patients and
family members in terms of quality and length of life, as well as treat-
ment costs. Patients with cancer who participate more actively in the
decision‐making process and those who experience effective SDM
may fare better with regard to physical and mental health, and quality
of life, and tend to report greater patient satisfaction, less distress, and
less regret.4,5 Conversely, more control by physicians was associated
with poorer reported health.6Psycho‐Oncology. 2017;26:1972–1979.rary.com/journal/pon
COLLEY ET AL. 1973The Control Preferences Scale (CPS) was developed to assess the
degree of control an individual prefers and actually exerts in the con-
text of treatment decision making.7 It has emerged as one of the most
commonly used instruments to assess decision‐making role. Patients'
preferred and actual decision‐making roles are typically reported as
“active,” “collaborative,” or “passive” depending on their degree of
preferred and actual involvement in decision making.
In oncology patients, several associations have been described
between patient characteristics and decision‐making role. A meta‐
analysis of CPS data fromover 3400oncology patients found that youn-
ger individuals and those with more education tended to prefer a more
active decision‐making role, while women were less likely to describe
their role as active despite expressing a preference for a more active
role.8 In other studies, patients with poorer general health, more
advanced stages of disease, lower physical functioning, and more
comorbidities tended to prefer and actually play a less active role.7,9,10
Psychological characteristics may also influence decision‐making role
preferences and behaviors. In several studies that examined the
relationships between emotional state, depression, anxiety, and deci-
sion‐making roles, a passive role was associated with higher levels of
depression,11,12 amorenegativemood, andgreatermooddisturbance.12
While previous work has established that certain demographic and
psychological factors are related to patient involvement in decision
making, less is known about how coping relates to role. According to
Lazarus and Folkman, coping comprises those thoughts and behaviors
used to manage the internal and external demands of situations that an
individual appraises as stressful.13 When faced with a threat, such as a
diagnosis of cancer or the prospect of choosing between two or more
treatment regimens, patients use varied coping strategies to manage
the stressor. While numerous ways of describing and grouping various
coping strategies have been described, one of the most widely used
categorizations is that of engagement vs disengagement coping.14
Engagement coping describes a strategy of coping that involves both
problem‐focused coping (targeted at the stressor itself) and emotion‐
focused coping (efforts to minimize distress triggered by the stressor).
For example, a problem‐focused approach to coping with cancer treat-
ment option may involve soliciting information about different treat-
ments, while an emotion‐focused coping approach may include
seeking emotional support from a loved one.
The other broad category of coping is disengagement coping,
which involves strategies like avoidance, denial, and wishful thinking
and may manifest as acting as though the stressor does not exist.
Disengagement coping is generally ineffective in reducing distress in
the long term.14 The process of deliberation itself has been suggested
to represent a multidimensional coping process.15,16 In theory, more
active participation in treatment decision making may represent an
engagement coping strategy, while more passive involvement may sig-
nify a disengagement coping strategy. However, limited prior work has
examined empirically the relationship between treatment decision
making in oncology patients and coping strategies.17
Factors such as gender, age, personality, and coping style may all
influence one's appraisal of a threat and potential outcomes.18 Indeed,
recent work has shown that personality, defined as “dimensions of
individual differences in tendencies to show consistent patterns of
thoughts, feelings, and actions,” may be related to a patient's copingstrategy or their capacity for coping.19–21 In theory, personality traits
should influence patients' preferences and behaviors with regard to
cancer treatment decision making because they influence a patient's
coping methods.14 As suggested recently, an understanding of coping
strategies may lead to a more nuanced concept of decision‐making
role.22 Therefore, it is important to understand a patient's decision‐
making role in relation to coping and personality traits. To our knowl-
edge, no study has examined the relationships between coping
approaches, personality traits, and decision‐making roles among
patients with various cancer diagnoses.
Therefore, the purposes of this study, in a sample of patients
undergoing chemotherapy (CTX) for breast, gastrointestinal (GI), lung,
or gynecological cancer were to (1) describe associations between
demographics and decision‐making role, (2) examine relationships
between psychological characteristics (anxiety and depression) and
decision‐making role, and (3) identify relationships between decision‐
making role and psychosocial adjustment characteristics, such as
coping style, personality, and mental adjustment to cancer.2 | METHODS
2.1 | Patients and settings
This cross‐sectional analysis used data from a larger, longitudinal study
that evaluated the symptom experience of oncology outpatients
receiving CTX.23
Eligible patients were 18 years or older; had a diagnosis of breast,
GI, gynecological, or lung cancer; had received CTX within the preced-
ing 4 weeks; were scheduled to receive at least 2 additional cycles of
CTX; were able to read, write, and understand English; and gave writ-
ten informed consent. Patients were recruited from 2 Comprehensive
Cancer Centers, 1 Veteran's Affairs hospital, and 4 community‐based
oncology programs. For the present analyses, a total of 1553 patients
were approached and 941 consented to participate (60.1% response
rate). The major reason for refusal was being overwhelmed with their
cancer treatment.
Of the 941 participants, 862 completed the CPS. Of these, 765
(88.7%) were concordant in terms of their actual and preferred roles
and were included in this analysis. Throughout this paper, “role” refers
to those patients whose preferred role matched their actual role. The
majority of patients had a collaborative role (56.3%), with
fewer patients preferring either the active (23.3%) or passive (20.4%)
role (Table 1).2.2 | Instruments
2.2.1 | Demographic characteristics
A demographic questionnaire obtained information on age, gender,
ethnicity, marital status, living arrangements, education, employment
status, and income.2.2.2 | Clinical characteristics
The Karnofsky Performance Status (KPS) scale is widely used to evalu-
ate functional status in patients with cancer and has well‐established
TABLE 1 Demographic and clinical characteristics by decision‐making role among patients with concordant roles (n = 765)
Characteristic
Active (1),
n = 178, 23.3%
Collaborative (2),
n = 431, 56.3%
Passive (3),
n = 156, 20.3%
StatisticsMean (SD) Mean (SD) Mean (SD)
Age, y 53.7 (11.8) 57.6 (11.1) 58.9 (12.5) F = 9.9; P < .0001; 1 < 2 and 3
Education, y 16.7 (3.1) 16.3 (3.0) 15.8 (3.0) F = 4.1; P = .017
Karnofsky Performance Status score 80 (11.7) 81 (12.3) 80.1 (12.1) F = 0.2; P = .654
Number of comorbidities 2.2 (1.4) 2.5 (1.4) 2.4 (1.3) F = 3.2; P = .040; 1 < 2
Self‐Administered Comorbidity Questionnaire score 5.2 (3.1) 5.7 (3.2) 5.3 (2.8) F = 2.1; P = .122
Time since cancer diagnosis, y 2.0 (3.4) 2.3 (4.2) 2.0 (3.6) F = 0.4; P = .673
Median time since cancer diagnosis, y 0.44 0.45 0.43
No. of prior cancer treatments 1.9 (1.5) 1.7 (1.5) 1.6 (1.6) F = 0.4; P = .660
No. of metastatic sites including lymph node involvement 1.2 (1.3) 1.2 (1.2) 1.4 (1.3) F = 1.6; P = .212
% (N) % (N) % (N)
Gender
Female 81 (144) 80 (343) 71 (111) χ2 = 5.8; P = .056
Male 19 (34) 20 (88) 29 (45)
Ethnicity
White 74 (131) 72 (201) 66 (100) χ2 = 3.4; P = .764
Black 6 (10) 7 (30) 9 (14)
Asian or Pacific Islander 10 (18) 12 (49) 14 (21)
Hispanic mixed or other 10 (18) 10 (40) 10 (16)
Married or partnered (% yes) 68 (120) 68 (291) 64 (99) χ2 = 0.7; P = .658
Currently employed (% yes) 40 (71) 36 (153) 28 (43) χ2 = 5.6; P = .062
Income
<$30 000+ 17 (28) 16 (63) 17 (23) KW, P = .019
$30 000 to <$70 000 14 (22) 20 (78) 32 (44)
$70 000 to <$100 000 16 (25) 15 (59) 16 (22)
≥$100 000 53 (86) 49 (191) 36 (50)
Cancer diagnosis
Breast 49 (87) 39 (167) 30 (47) χ2 = 17.4; P = .008a
Gastrointestinal 27 (48) 30 (128) 35 (55)
Gynecological 17 (31) 19 (80) 17 (27)
Lung 7 (12) 13 (56) 17 (27)
Type of prior cancer treatment
No prior treatment 14.1 (25) 21.5 (91) 25.7 (39) χ2 = 8.3; P = .219
Only surgery, CTX, or RT 49.2 (87) 43.3 (183) 40.8 (62)
Surgery and CTX, or surgery and RT, or CTX and RT 20.9 (37) 21.7 (92) 18.4 (28)
Surgery and CTX and RT 15.8 (28) 13.5 (57) 15.1 (23)
Abbreviations: CTX, chemotherapy; KW, Kruskal‐Wallis; RT, radiation therapy; SCQ, Self‐Administered Comorbidity Questionnaire; SD, standard deviation.
aCompared with patients with gastrointestinal or lung cancer, patients with breast cancer were more likely to prefer an active role.
1974 COLLEY ET AL.validity and reliability. Using the KPS, patients rated their functional
status from the lowest possible score of 30 (“I feel severely disabled
and need to be hospitalized”) to the highest possible score of 100
(“I feel normal; I have no complaints or symptoms”).24
The Self‐Administered Comorbidity Questionnaire (SCQ) consists
of 13 common medical conditions simplified into a language that can
be understood without prior medical knowledge.25 Patients indicated
if they have the condition; if they received treatment for it (proxy for
disease severity); and if it limited their activities (indication of func-
tional limitations). For each condition, the patient can receive a maxi-
mum of 3 points. The total SCQ score ranges from 0 to 39. The SCQ
has well‐established validity and reliability.262.2.3 | Control Preferences Scale
The CPS, developed by Degner and Sloan, was used to assess patients'
preferred and actual roles in decision making about their cancer treat-
ment.7 Patients responded to 2 questions (ie, the role they have actually
been playing in dealing with their cancer diagnosis and the role they
would have preferred) by choosing 1 of 5 statements (ie, A = I prefer to
make the decisions about which treatments I will receive; B = I prefer
to make the final decision about my treatment after seriously consider-
ing my doctor's opinion; C = I prefer to leave all decisions regarding my
treatment to my doctor; D = I prefer to have my doctor make the final
decision about which treatment will be used, but seriously consider my
opinion; and E = I prefer that my doctor and I share responsibility for
COLLEY ET AL. 1975deciding which treatment is best for me). Patients who preferred state-
ments A or B were classified as active patients, those who preferred
statement C or Dwere considered passive patients, and those who pre-
ferred statementEwere classified as collaborative patients. TheCPShas
well‐established validity and reliability in oncology patients.82.2.4 | Psychological symptoms
The Center for Epidemiological Studies‐Depression scale (CES‐D)
consists of 20 items selected to represent the major symptoms in the
clinical syndrome of depression. A total score can range from 0 to
60, with scores ≥16 indicating the need for individuals to seek clinical
evaluation for major depression.27 The CES‐D has well‐established
validity and reliability.27 In the current study, the Cronbach α for the
CES‐D total score was 0.89.
TheSpielberger State‐TraitAnxiety Inventories (STAI‐TandSTAI‐S)
each have 20 items that are rated from 1 to 4. The summed scores for
each scale can range from 20 to 80. The STAI‐S measures a person's
temporary anxiety response to a specific situation or how anxious or
tense a person is “right now” in a specific situation. The STAI‐T mea-
sures a person's predisposition to anxiety as part of one's personality.
Cutoff scores of ≥31.8 and ≥32.2 suggest high levels of trait and state
anxiety, respectively.28,29 In the current study, the Cronbach α's for the
STAI‐T and STAI‐S were 0.92 and 0.96, respectively.2.2.5 | Psychosocial adjustment characteristics
The Connor‐Davidson Resilience Scale is a 10‐item instrument, scored
on a 5‐point Likert scale, that evaluates self‐perceived ability to handle
adversity (eg, “I am able to adapt when changes occur”).30 Items are
scored on a 5‐point Likert scale (“not true at all” to “true nearly all of
the time”). Total scores range from 0 to 40, with higher scores indica-
tive of higher self‐perceived resilience. In this study, the Cronbach α
for the Connor‐Davidson Resilience Scale was 0.90.
The Brief COPE scale is a 28‐item instrument, rated on a 4‐point
Likert scale, that was designed to assess a broad range of coping
responses among adults for all diseases.31 Higher scores indicate
greater use of the various coping strategies. In total, 14 dimensions
are evaluated using this instrument (with their respective Cronbach
α's), namely, self‐distraction (0.46), active coping (0.75), denial (0.72),
substance use (0.87), use of emotional support (0.77), use of instru-
mental support (0.77), behavioral disengagement (0.57), venting
(0.65), positive reframing (0.79), planning (0.74), humor (0.83), accep-
tance (0.68), religion (0.92), and self‐blame (0.73). Each dimension is
evaluated using 2 items. The Brief Cope has well‐established validity
and reliability in oncology patients.32
The Mental Adjustment to Cancer Scale, consisting of 40 items
each rated on a 4‐point Likert scale, was designed to measure patients'
cognitive and behavioral responses to a cancer diagnosis and its
treatment.33,34 Five subscales were originally derived—fighting spirit,
anxious preoccupation, helplessness/hopelessness, fatalism, and
avoidance. These can also be subsumed under higher‐order subscales,
termed positive and negative adjustment.34 The Cronbach α's for 4 of
the 5 subscales were as follows: 0.81 for fighting spirit, 0.62 for anx-
ious preoccupation, 0.82 for helpless/hopeless, and 0.53 for fatalism(as the avoidance subscale consists of only 1 item, a Cronbach α could
not be calculated for this subscale).
The NEO Five‐Factor Inventory (NEO‐FFI) is a 60‐item instrument
that was used to assess personality.35 Factor analytic studies found
that the NEO‐FFI measures the “Big Five” domains of personality—ie,
Neuroticism (self‐reproach, negative affect), Extraversion (sociability,
positive affect, activity level), Openness to experience (aesthetic and
intellectual interests, unconventionality), Agreeableness (prosocial or
non‐antagonistic orientation), and Conscientiousness (dependability,
orderliness, goal‐striving). Higher scores indicate higher levels of each
domain. In this study, the Cronbach α's for the NEO‐FFI were as fol-
lows: 0.87 for Neuroticism, 0.80 for Extraversion, 0.77 for Openness
to experience, 0.76 for Agreeableness, and 0.84 for Conscientiousness.2.3 | Study procedures
The study was approved by the Committee on Human Research at the
University of California, San Francisco, and by the institutional review
board at each of the study sites. Eligible patients were approached by a
research staff member in the infusion unit to discuss participation in
the study. Written informed consent was obtained from all patients.
Patients who had received CTX within the preceding 4 weeks com-
pleted questionnaires in their homes during the week prior to the
administration of the next cycle of CTX (ie during the recovery period).
Medical records were reviewed for disease and treatment information.2.4 | Data analysis
Data were analyzed using SPSS version 22 (IBM, Armonk, New York).
Descriptive statistics and frequency distributions were calculated for
demographic and clinical characteristics. Analysis of variance, χ2 tests,
and Kruskal‐Wallis tests with Bonferroni corrected post hoc contrasts
were used to evaluate for differences among the patients based on
their decision‐making roles. To address the issue of multiple testing,
a more conservative P‐value of <.01 was considered statistically signif-
icant. All calculations used actual values and adjustments were not
made for missing data, which were assumed to be random. Therefore,
the cohort for each analysis depends on the largest set of complete
data among each decision‐making role group.
While theoretical differences exist between factors that may be
associated with preferred role versus those associated with actual role,
initial analysis of these data showed that the concordance rate
between preferred and actual role was nearly 90%. On the basis of this
finding, there was limited statistical power to detect differences
between concordant and discordant patients with regard to the vari-
ables of interest. Therefore, analyses were constrained to those with
a concordant role (n = 765).
Multinomial logistic regression, in which the dependent variable
was decision‐making role, was conducted in which the demographic
and clinical variables were forced into the model (age, education,
gender, and cancer type). These variables were either significant in
univariate analyses or considered highly relevant to this analysis based
on prior literature. Since coping and personality were the factors of
primary interest to this study, coping and personality variables thatwere
significant in univariate analyses were considered for inclusion in the
1976 COLLEY ET AL.multinomial regression, based on a backward stepwise elimination strat-
egy. Variables were removed from the model if their P‐value was >0.05.3 | RESULTS
3.1 | Differences in demographic and clinical
characteristics
As shown in Table 1, patients who had a passive role were more likely
to be older, less educated, and have a lower income. However, deci-
sion‐making role did not differ significantly by gender or ethnicity.TABLE 2 Physical and psychological symptoms by decision‐making role am
Characteristic
Active (1),
n = 178, 23.3%
Mean (SD)
Center for Epidemiologic Studies‐Depression Scale 12.6 (9.8)
Spielberger State‐Trait Anxiety Inventories
State anxiety 33.8 (13.3)
Trait anxiety 34.6 (11.0)
TABLE 3 Psychosocial adjustment characteristics by decision‐making role
Characteristic
Active (1),
n = 178, 23.3%
Collabor
n = 431
Mean (SD) Mean
Connor‐Davidson Resilience Scale 30.3 (6.2) 30.4
Brief COPE
Active coping 4.1 (1.6) 4.0
Planning coping 3.4 (1.8) 3.4
Positive reframing 3.4 (1.9) 3.5
Acceptance 4.6 (1.3) 4.7
Humor 2.8 (1.9) 2.3
Religion 2.6 (2.3) 3.0
Emotional support 4.3 (1.5) 4.5
Instrumental support 3.2 (1.8) 3.5
Self‐distraction 3.5 (1.6) 3.4
Denial 0.5 (1.1) 0.5
Venting 2.0 (1.6) 2.0
Substance use 0.2 (0.5) 0.2
Behavioral disengagement 0.2 (0.6) 0.2
Self‐blame 0.9 (1.3) 0.8
Mental Adjustment to Cancer
Fighting spirit 51 (5.7) 52.1
Anxious preoccupation 23 (4.2) 23.5
Helplessness/hopelessness 8.6 (3.0) 8.9
Fatalism 16.2 (3.2) 17.3
Avoidance 1.5 (0.7) 1.5
Positive adjustment 52.9 (6.2) 54.6
Negative adjustment 28.9 (7.5) 30.1
NEO Five‐Factor Inventory
Neuroticism 42 (11.2) 42.2
Extraversion 53.0 (11.0) 53.5
Openness 57.1 (11.6) 55.3
Agreeableness 54.7 (10.4) 55.7
Conscientiousness 51.5 (9.8) 50.9Decision‐making role also varied significantly by cancer type.
Patients who had a passive role were more likely to have lung or GI
cancer than breast cancer. Compared with patients who had an active
role, patients who had a collaborative role had more comorbid condi-
tions. Decision‐making role did not vary significantly by KPS score,
number of metastatic sites, or years since diagnosis.
3.2 | Differences in physical and psychological
symptoms
Decision‐making role groups did not vary significantly with regard to
depression, state, or trait anxiety (Table 2).ong patients with concordant roles (n = 765)
Collaborative (2),
n = 431, 56.3%
Passive (3),
n = 156, 20.3%
StatisticsMean (SD) Mean (SD)
12.5 (9.4) 12.4 (9.4) F = 0.02; P = .980
33.4 (12.0) 33.1 (12.5) F = 0.09; P = .907
34.9 (10.6) 34.6 (10.2) F = 0.15; P = .861
among patients with concordant roles (n = 765)
ative (2),
, 56.3%
Passive (3),
n = 156, 20.3%
Statistics(SD) Mean (SD)
(6.3) 28.8 (6.4) F = 3.8; P = .022
(1.6) 3.5 (1.8) F = 8.7; P < .001; 1 and 2 > 3
(1.7) 2.7 (1.9) F = 8.9; P < .001; 1 and 2 > 3
(1.9) 2.8 (1.9) F = 8.3; P < .001; 1 and 2 > 3
(1.3) 4.6 (1.4) F = 1.1; P = .339
(2.0) 1.9 (2.0) F = 8.4; P < .001; 1 and 2 > 3
(2.3) 3.0 (2.2) F = 2.1; P = .122
(1.6) 3.9 (1.9) F = 7.2; P = .001; 2 > 3
(1.7) 2.9 (1.9) F = 5.5; P = .004; 2 > 3
(1.7) 3.4 (1.9) F = 0.5; P = .608
(1.1) 0.4 (1.0) F = 0.9; P = .337
(1.6) 1.6 (1.5) F = 2.7; P = .068
(0.7) 0.2 (0.9) F = 0.5; P = .629
(0.7) 0.2 (0.6) F = 0.4; P = .667
(1.2) 0.8 (1.2) F = 0.2; P = .819
(5.7) 51.4 (5.5) F = 2.3; P = .104
(3.5) 22.8 (2.3) F = 2.6; P = .074
(2.9) 9.2 (2.9) F = 1.6; P = .211
(3.1) 18.7 (3.4) F = 24.2; P < .001; 1 < 2 < 3
(0.8) 1.5 (0.8) F = 0.3; P = .736
(6.2) 54.2 (6.0) F = 4.2; P = .015
(7.1) 30.4 (7.3) F = 2.0; P = .136
(10.4) 44.0 (10.0) F = 1.6; P = .201
(11.2) 52.3 (11.5) F = 0.6; P = .552
(11.2) 53.0 (10.6) F = 5.5; P = .004; 1 > 3
(11.8) 55.3 (10.9) F = 0.5; P = .630
(10.2) 50.4 (10.9) F = 0.4; P = .655
TABLE 4 Multinomial logistic regression: final model
Effect
Model Fitting Criteria
Likelihood Ratio Tests
−2 Log Likelihood of Reduced Model χ2 df Significance
Intercept 1285.660 0.000 0 —
Cancer type 1289.875 4.215 6 .648
Gender 1287.161 1.501 2 .472
Age 1293.332 7.672 2 .022
Education 1286.566 0.906 2 .636
Positive reframing 1298.765 13.105 2 .001
Fatalism 1318.795 33.135 2 <.001
COLLEY ET AL. 19773.3 | Differences in psychosocial adjustment
characteristics
Table 3 shows the relationship between decision‐making role and resil-
ience and levels of fatalism. Compared with those who had a collabo-
rative role, patients who had a passive role were less resilient. Of all
3 groups, the group with patients who had a passive role had the
highest levels of fatalism. Decision‐making role varied significantly by
coping style with patients who had a passive role being less likely than
those who had an active or collaborative role to use the following cop-
ing strategies: active coping, planning, positive reframing, and humor.
Furthermore, patients who had a passive role were less likely than
those who had a collaborative role to use emotional or instrumental
support‐oriented coping strategies. In terms of personality, differences
in decision‐making role were significantly related to only 1 of the 5
personality dimensions—ie, patients who had a passive role had lower
levels of Openness to Experience than those who had an active role.
Last, patients who had a collaborative role reported higher levels of
positive adjustment than those who had an active role.3.4 | Multinomial regression analysis
The overall model was tested with a likelihood ratio test and was sig-
nificant (χ2 = 73.01; df = 16; P < .001). The overall goodness‐of‐fit devi-
ance test had a very high P‐value (.935), also indicating a good model
fit. The overall model had a McFadden pseudo‐R2 of 0.054, indicating
that the model explained approximately 5% of the variance in decision‐
making role.
The final model (Table 4) includes the 4 variables that were forced
into the model (age, education, gender, and cancer type). The only 2
variables of the coping and personality variables that were retained
in the final model from the backward stepwise approach were fatalism
and positive reframing. Gender, education, and cancer type did not
make significant unique contributions to the model, whereas age
(P = .022), fatalism (P < .001), and positive reframing (P = .001) did
make significant unique contributions to the model.
Pairwise comparisons revealed that older patients were more
likely to be in the collaborative role group than in the active role group.
All 3 pairwise comparisons were significant for fatalism, ie, patients
who had a collaborative role endorsed higher levels of fatalism than
those who had an active role, and patients who had a passive
role endorsed higher levels of fatalism than those who had either an
active role or a collaborative role. Finally, patients in the collaborativerole group endorsed higher levels of positive reframing than those in
the passive group.4 | CONCLUSIONS
Several new findings emerged from this study, particularly with respect
to the relationship between psychosocial adjustment characteristics
and decision‐making roles in oncology patients undergoing CTX.
Compared with those who had an active role, patients who had a
passive role were less likely to use engagement coping strategies
(active coping, planning coping, and positive reframing) and had a less
open personality. This confirms our hypothesis that coping and deci-
sion‐making role are strongly related. Prior work has tended to theorize
coping approaches and decision‐making role as separate phenomena;
however, our data indicate that decision‐making role and coping style
may be intimately connected as part of a singular process.
It is possible that decision‐making role may indeed be a
subcomponent of one's overall coping approach. Carver's definition
of engagement coping includes a patient who asks questions and seeks
information from their physician.14 It then follows that a patient who
asks questions and participates in SDM would identify their role as
an active role. Therefore, on the basis of the relationship between
engagement‐type coping strategies and active role in our data, we the-
orize that decision‐making role is 1 component of a coping style.
The relationship between decision‐making roles and coping sug-
gests that the degree of involvement in decision making may be a man-
ifestation of the patient's typical (or most prominent) coping
mechanisms. The finding that decision‐making preferences are closely
associated coping styles suggests, as Singhnotedpreviously, that under-
lying traits may be more responsible for enduring decision‐making
styles.8 Thus, overemphasizing the “active” role may be rooted in mis-
taken assumptions about the malleability of decision‐making styles.
While our data suggest that decision‐making role preference may be
more of a trait‐like characteristic, little is known about whether
individuals' decision‐making role preferences change over the course
of illness. To address the role of time and disease course in decision‐
making rolepreference, longitudinal prospective studies shouldbedone.
Patients with a passive role tended to have a more fatalistic
stance, which is consistent with the work by Shields and colleagues.36
While the term “fatalism” has evoked a negative connotation in the
past, recently, the construct it represents was reconceptualized as hav-
ing both positive and negative valences.37 For instance, “fatalism” can
1978 COLLEY ET AL.take the form of acceptance (eg, “I've put myself in the hands of God”),
reframing (eg, “I've had a good life, what's left is a bonus”), or nega-
tively, as a lack of control or self‐efficacy (eg, “I feel I can't control
what's happening to me.”). Instead of a resignation to a predetermined
fate, adopting a fatalistic attitude may be a logical response to previous
poor health outcomes personally or in one's community.37 In this way,
the relationship between fatalism and preference for a more passive
role may be influenced by patients' past experience with health and
disease and may serve as a mechanism by which patients cope with
navigating the cancer treatment process. By evaluating these factors
in the same sample, this study adds to our understanding of the rela-
tionships between decision‐making role and coping strategies, fatalism,
and personality. Prior work by Powe et al has shown that fatalism may
be modifiable and may thereby serve as a means to engage patients
further in treatment decision making.38 Given the unique contribution
of fatalism to the model, focusing on interventions to address fatalistic
beliefs may be an important way to enhance patient participation.
In addition to a more fatalistic stance, those patients who had a
more passive role tended not to use a humor‐based coping strategy—
to our knowledge, a previously unreported finding. Humor is generally
seen as an adaptive coping mechanism and has been associated with
positive psychological changes following a diagnosis of cancer.31 This
finding, along with the other data from the present study, suggests that
patients who prefer a passive role may use less adaptive coping
strategies.
Our findings are consistent with previous work that found that
older age and lower education were associated with preference for a
passive decision‐making role.8 However, this study contributes a
slightly different impression of the preferences of oncology patients
with regard to decision‐making role. Compared with a pooled analysis
of data from 3491 patients,8 in our study, a higher percentage of
patients preferred a collaborative role (56% in our study vs 34% in
Singh et al), and more of them (90% vs 84%) actually played their pre-
ferred role. It is possible that the higher percentage of patients who
played a collaborative role and the level of concordance between pre-
ferred and actual role in our study was influenced by changing expec-
tations for involvement and an increasing emphasis on SDM in health
care.36 Higher education is known to be related to a preference for a
more active role,39 so it is possible that the higher‐than‐average level
of education of this sample affected these findings. Furthermore,
unlike previous research, our study found no significant relationship
between gender and decision‐making role preference.8
With regard to clinical characteristics, decision‐making role was
associated with the type of cancer and number of comorbidities. Con-
sistent with a previous report,40 our study found that breast cancer
patients were more likely to play a collaborative or active role than
patients with other cancer types. Shields et al hypothesized that
greater public awareness and the wealth of available information about
breast cancer may help foster a sense of greater activism in these
patients.36 However, differences were not found between preferred
role and number of metastatic sites. These previously unstudied rela-
tionships suggest that one's current health status, rather than stage
of disease, may be more important in determining patients' level of
involvement or support needed. Further investigation into the role that
overall functioning versus disease severity plays in SDM is warranted.Limitations of this study include data from a single time point,
which prevents longitudinal inference. Future studies should collect
data about decision‐making roles over time to identify trends in how
the progression of treatment and/or illness, relationships with clini-
cians, and other factors may be related to a patient's role. In addition,
as patients were not asked about their decision‐making role in relation
to a specific treatment decision, it is possible that variability in the
kinds of treatment decisions patients faced may have influenced the
findings. Despite the fact that this study included a sample recruited
from 6 different sites, the patients tended to overrepresent some
demographic groups. The majority of patients in this study were highly
educated, had a high income, were Caucasian, and had breast cancer.
Moreover, the refusal rate of 40% could have led to a selection bias;
ie, participants in this study may have been those who felt more able
to complete a series of questionnaires while undergoing CTX. These
characteristics suggest that our findings may not be generalizable.
Therefore, further work is needed to identify and address disparities
and barriers to participation in SDM by underserved groups, including
those not represented by the current sample.
In conclusion, this study found that coping is related to decision
role even after controlling for demographic characteristics. Given the
potential benefits of playing a more active role,1 it is important that cli-
nicians find ways to engage all patients in the decision‐making process
while not abandoning those who prefer a passive role by
overemphasizing patient autonomy. Clinicians should be aware that
some patients might cope with their illness by seeking support and
by playing a less active role in decision making. These preferences
may be influenced by fatalism, personality, coping style, illness factors,
culture, and demographics—indicating that decision‐making role pref-
erence is a complex and multifaceted entity. Clinicians should individ-
ualize their approach, finding ways to engage all patients in decision
making to the extent that patients feel supported and valued, while
maintaining awareness that participation in SDM could be a way for
patients to cope with and understand their illness. Further study is
warranted to explore the ways in which decision‐making role may
change with time and to determine if role or coping style may be
influenced by interventions designed to teach adaptive coping skills.
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